Ewa Haładyj

机构：Eli Lilly (United States) · ORCID：0000-0002-5677-6292

发表论文 67 篇 · 总被引 731 次 · h-index 15

代表论文

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience (2023 · Journal of Clinical Medicine · 被引 43)
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis (2023 · Rheumatology and Therapy · 被引 19)
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study (2024 · Lara D. Veeken · 被引 11)
Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study (2024 · Rheumatology and Therapy · 被引 5)
Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset (2023 · Clinical and Experimental Rheumatology · 被引 5)
Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study (2025 · The Journal of Rheumatology · 被引 4)